Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
European Journal of Nuclear Medicine and Molecular Imaging1993Vol. 20(8), pp. 716–731
Citations Over TimeTop 1% of 1993 papers
E. P. Krenning, Dik J. Kwekkeboom, Willem H. Bakker, Wout A. P. Breeman, P.P.M. Kooij, H.Y. Oei, M. van Hagen, P.T.E. Postema, Marion de Jong, Jean Claude Reubi, T. J. Visser, Ambroos E.M. Reijs, Leo J. Hofland, Jan W. Koper, S. W. J. Lamberts
Related Papers
- → Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life(2017)44 cited
- → Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies(2020)6 cited
- → Methylation of somatostatin receptor 2 gene in neuroendocrine tumours as a predictor of tumour response to peptide receptor radionuclide therapy(2019)1 cited
- Peptide receptor radionuclide therapy: current status and future directions(2005)
- Octreotide labeled with~(99)Tc~m-for detecting somatostatin receptor positive tumors: preparation, identification and preliminary clinical application(2000)